首页> 外文OA文献 >P3-019: Serum Cathepsin B (CB) is prognostic and may predict response to therapy in chemotherapy-naive PS2 advanced NSCLC patients treated on two concurrent phase III trials of paclitaxel poliglumex (PPX) vs control treatments (STELLAR 3 and 4)

【2h】

P3-019: Serum Cathepsin B (CB) is prognostic and may predict response to therapy in chemotherapy-naive PS2 advanced NSCLC patients treated on two concurrent phase III trials of paclitaxel poliglumex (PPX) vs control treatments (STELLAR 3 and 4)

机译：P3-019：血清紫红素B（CB）可以预后，并且可以预测在两项同时进行的紫杉醇poliglumex（PPX）与对照治疗同时进行的III期临床试验中，未接受过化疗的PS2晚期NSCLC患者的治疗反应（STELLAR 3和4）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Ross Helen J.; Oldham Fred; Bandstra B; Salindac L; Bonomi Philip; Singer Jack;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. [J] . Langer CJ, OByrne KJ, Socinski MA, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2008,第6期

机译：III期试验比较了紫杉醇poliglumex（CT-2103，PPX）联合卡铂与标准紫杉醇和卡铂在未接受化疗的PS 2初发性晚期非小细胞肺癌患者中的治疗。
2. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. [J] . Langer CJ, OByrne KJ, Socinski MA, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2008,第6期

机译：III期试验比较了紫杉醇poliglumex（CT-2103，PPX）联合卡铂与标准紫杉醇和卡铂在未接受化疗的PS 2初发性晚期非小细胞肺癌患者中的治疗。
3. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. [J] . OBrien ME, Socinski MA, Popovich AY, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2008,第7期

机译：比较单药紫杉醇Poliglumex（CT-2103，PPX）与单药吉西他滨或长春瑞滨治疗PS 2初治性晚期非小细胞肺癌患者的随机III期试验。
4. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy [O] . Qing Zhou, Ming Chen, Gang Wu, 2020

机译：Gemstone-301：CS1001的III期临床试验作为局部晚期/不可切除（第III阶段）非小细胞肺癌（NSCLC）在先前同时/顺序化学疗法后没有疾病进展的患者的固结治疗
5. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer [O] . Langer, C. J., O'Byrne, Kenneth J., Socinski, M. A., 2008

机译：III期试验比较紫杉醇poliglumex（CT-2103，PPX）联合卡铂与标准紫杉醇和卡铂治疗未曾化疗的PS 2晚期非小细胞肺癌

P3-019: Serum Cathepsin B (CB) is prognostic and may predict response to therapy in chemotherapy-naive PS2 advanced NSCLC patients treated on two concurrent phase III trials of paclitaxel poliglumex (PPX) vs control treatments (STELLAR 3 and 4)

著录项

相似文献

相关主题

期刊订阅